Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer

Maurizio Brausi, Antony Blatnik, Mark S. Soloway

Research output: Contribution to journalArticle

Abstract

Methotrexate (MTX) has activity in transitional cell carcinoma (TCC) in man and some have suggested an advantage of high-dose methotrexate versus the standard dose in controling tumor growth and prolonging survival. MBT-2, a poorly differentiated TCC induced by the carcinogen FANFT, is both grossly and histologically similar to human TCC and has been used as an animal model. One hundred twenty C3HIHE female mice were injected in the hind limb with 7.5 × 104 MBT-2 tumor cells. When palpable tumors developed in all animals, therapy was initiated. Animals were randomized into a control group and nine treatment groups as follows: cisplatin (DDP), MTX 32 mg, MTX 50 mg, MTX 80 mg, DDP + MTX 32, MTX 50 + Leucovorin, MTX 80 + Leucovorin, DDP + MTX 50 + Leucovorin, DDP + MTX 80 + Leucovorin. The combination of MTX 50 mg with Leucovorin + DDP and DDP alone were the two most effective regimens in controlling tumor growth and prolonging survival. No statistically significant difference was observed between the group treated by high-dose MTX alone and those treated by low-dose MT X. No toxicity was observed men when high doses of MTX were used.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalUrology
Volume35
Issue number3
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Methotrexate
Cisplatin
Leucovorin
Transitional Cell Carcinoma
FANFT
Neoplasms
Survival
Growth
Carcinogens
Extremities
Animal Models

ASJC Scopus subject areas

  • Urology

Cite this

Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer. / Brausi, Maurizio; Blatnik, Antony; Soloway, Mark S.

In: Urology, Vol. 35, No. 3, 01.01.1990, p. 253-256.

Research output: Contribution to journalArticle

Brausi, Maurizio ; Blatnik, Antony ; Soloway, Mark S. / Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer. In: Urology. 1990 ; Vol. 35, No. 3. pp. 253-256.
@article{32db2cde580749c9b679cafa1fa4dc36,
title = "Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer",
abstract = "Methotrexate (MTX) has activity in transitional cell carcinoma (TCC) in man and some have suggested an advantage of high-dose methotrexate versus the standard dose in controling tumor growth and prolonging survival. MBT-2, a poorly differentiated TCC induced by the carcinogen FANFT, is both grossly and histologically similar to human TCC and has been used as an animal model. One hundred twenty C3HIHE female mice were injected in the hind limb with 7.5 × 104 MBT-2 tumor cells. When palpable tumors developed in all animals, therapy was initiated. Animals were randomized into a control group and nine treatment groups as follows: cisplatin (DDP), MTX 32 mg, MTX 50 mg, MTX 80 mg, DDP + MTX 32, MTX 50 + Leucovorin, MTX 80 + Leucovorin, DDP + MTX 50 + Leucovorin, DDP + MTX 80 + Leucovorin. The combination of MTX 50 mg with Leucovorin + DDP and DDP alone were the two most effective regimens in controlling tumor growth and prolonging survival. No statistically significant difference was observed between the group treated by high-dose MTX alone and those treated by low-dose MT X. No toxicity was observed men when high doses of MTX were used.",
author = "Maurizio Brausi and Antony Blatnik and Soloway, {Mark S.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0090-4295(90)80044-N",
language = "English",
volume = "35",
pages = "253--256",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer

AU - Brausi, Maurizio

AU - Blatnik, Antony

AU - Soloway, Mark S.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Methotrexate (MTX) has activity in transitional cell carcinoma (TCC) in man and some have suggested an advantage of high-dose methotrexate versus the standard dose in controling tumor growth and prolonging survival. MBT-2, a poorly differentiated TCC induced by the carcinogen FANFT, is both grossly and histologically similar to human TCC and has been used as an animal model. One hundred twenty C3HIHE female mice were injected in the hind limb with 7.5 × 104 MBT-2 tumor cells. When palpable tumors developed in all animals, therapy was initiated. Animals were randomized into a control group and nine treatment groups as follows: cisplatin (DDP), MTX 32 mg, MTX 50 mg, MTX 80 mg, DDP + MTX 32, MTX 50 + Leucovorin, MTX 80 + Leucovorin, DDP + MTX 50 + Leucovorin, DDP + MTX 80 + Leucovorin. The combination of MTX 50 mg with Leucovorin + DDP and DDP alone were the two most effective regimens in controlling tumor growth and prolonging survival. No statistically significant difference was observed between the group treated by high-dose MTX alone and those treated by low-dose MT X. No toxicity was observed men when high doses of MTX were used.

AB - Methotrexate (MTX) has activity in transitional cell carcinoma (TCC) in man and some have suggested an advantage of high-dose methotrexate versus the standard dose in controling tumor growth and prolonging survival. MBT-2, a poorly differentiated TCC induced by the carcinogen FANFT, is both grossly and histologically similar to human TCC and has been used as an animal model. One hundred twenty C3HIHE female mice were injected in the hind limb with 7.5 × 104 MBT-2 tumor cells. When palpable tumors developed in all animals, therapy was initiated. Animals were randomized into a control group and nine treatment groups as follows: cisplatin (DDP), MTX 32 mg, MTX 50 mg, MTX 80 mg, DDP + MTX 32, MTX 50 + Leucovorin, MTX 80 + Leucovorin, DDP + MTX 50 + Leucovorin, DDP + MTX 80 + Leucovorin. The combination of MTX 50 mg with Leucovorin + DDP and DDP alone were the two most effective regimens in controlling tumor growth and prolonging survival. No statistically significant difference was observed between the group treated by high-dose MTX alone and those treated by low-dose MT X. No toxicity was observed men when high doses of MTX were used.

UR - http://www.scopus.com/inward/record.url?scp=0025219409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025219409&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(90)80044-N

DO - 10.1016/0090-4295(90)80044-N

M3 - Article

VL - 35

SP - 253

EP - 256

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -